Citizens raises Aquestive Therapeutics stock price target to $12 on extended patent protection
PositiveFinancial Markets

Citizens has raised the stock price target for Aquestive Therapeutics to $12, following the company's extended patent protection. This news is significant as it reflects confidence in the company's future prospects and the potential for increased revenue, which could benefit investors and the market.
— Curated by the World Pulse Now AI Editorial System